688137.SHG Suzhou Novoprotein Scientific Co. Ltd. A
- Market cap
- CNY 10.2B
- P/E
- -
- P/B
- 4.72x
- ROE
- -2.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688137.SHG undervalued?
Graham numberThe Graham number of Suzhou Novoprotein Scientific Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Suzhou Novoprotein Scientific Co. Ltd. A fundamental analysis
No fundamental analysis for Suzhou Novoprotein Scientific Co. Ltd. A yet.
Suzhou Novoprotein Scientific Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Suzhou Novoprotein Scientific Co. Ltd. A
Novoprotein Scientific Inc. researches, develops, produces, and sells raw materials and technology solutions for biopharmaceuticals enterprises. The company offers mRNA vaccine drug raw materials, immunodiagnostic and molecular diagnostic raw materials, gene and cell therapy, molecular research reagents, cytokines, target proteins, cell lines, reference antibody, recombinant antibodies, enzymes and reagents, matrix gel and culture medium, and protein and virus research relat…
Full company profileSuzhou Novoprotein Scientific Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Suzhou Novoprotein Scientific Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 180M | 342M | 265M | 153M | 128M | 146M | 157M |
| Gross Profit | 161M | 300M | 228M | 116M | 79.6M | 98.3M | 108M |
| Operating Income | 104M | 194M | 113M | -5.89M | -55.4M | -66.7M | -54.8M |
| EBITDA | - | - | 131M | 32.4M | -19.3M | -37.9M | -55.1M |
| Net Income | 83.0M | 149M | 90.7M | 12.8M | -54.4M | -77.8M | -58.4M |
| EPS | 1.58 | 2.83 | 1.29 | 0.18 | -0.78 | -1.11 | -0.84 |
| Balance Sheet | |||||||
| Total Assets | 185M | 513M | 2.33B | 2.30B | 2.22B | 2.15B | 2.14B |
| Total Liabilities | 81.7M | 153M | 133M | 110M | 116M | 117M | 140M |
| Shareholders' Equity | 103M | 360M | 2.20B | 2.19B | 2.10B | 2.03B | 2.00B |
| Cash & Short-term Investments | 68.6M | 189M | 930M | 864M | 647M | 711M | 734M |
| Cash Flow | |||||||
| Operating Cash Flow | 97.6M | 71.0M | 3.38M | 69.2M | 13.3M | -13.4M | - |
| Capital Expenditure | 11.8M | 70.0M | 36.8M | 44.9M | 44.9M | 78.9M | 46.6M |
| Free Cash Flow | 85.8M | 1.02M | -33.4M | 24.2M | -31.6M | -92.2M | -92.1M |
| Ratios | |||||||
| ROE | 80.6% | 41.4% | 4.1% | 0.6% | -2.6% | -3.8% | -2.9% |
| ROA | 44.9% | 29.0% | 3.9% | 0.6% | -2.5% | -3.6% | -2.7% |
| Net Profit Margin | 46.2% | 43.6% | 34.3% | 8.4% | -42.7% | -53.1% | -37.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Suzhou Novoprotein Scientific Co. Ltd. A dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 1, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | CNY 35.1M | 0.50 | - |
| 2023 | CNY 35.1M | 0.50 | 273.2% |
| 2022 | - | - | - |
| 2021 | CNY 16.3M | 0.31 | 10.9% |
| 2020 | CNY 1.03M | 0.02 | 1.2% |
| 2019 | CNY 155K | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Suzhou Novoprotein Scientific Co. Ltd. A
- Insiders 68.11%
- Institutions 6.56%
- Public & others 25.33%
- Shares outstanding 69.9M
- Free float 21.9M
Suzhou Novoprotein Scientific Co. Ltd. A company profile
- Company name
- Suzhou Novoprotein Scientific Co. Ltd. A
- Ticker
- 688137.SHG
- ISIN
- CNE100005NZ4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 696
- Fiscal year end
- December
- Address
- No.228, Yunchuang Road, Suzhou, China, 215299
- Phone
- 86 512 6391 9116
- Website
- novoprotein.com.cn
About Suzhou Novoprotein Scientific Co. Ltd. A
Novoprotein Scientific Inc. researches, develops, produces, and sells raw materials and technology solutions for biopharmaceuticals enterprises. The company offers mRNA vaccine drug raw materials, immunodiagnostic and molecular diagnostic raw materials, gene and cell therapy, molecular research reagents, cytokines, target proteins, cell lines, reference antibody, recombinant antibodies, enzymes and reagents, matrix gel and culture medium, and protein and virus research related products. It offers its products and services in the fields of biopharmaceuticals, mRNA vaccines and drugs, in vitro diagnostics, basic research of life sciences, and other areas. Novoprotein Scientific Inc. was founded in 2009 and is headquartered in Suzhou, China.
Suzhou Novoprotein Scientific Co. Ltd. A management
5- Dr. Huaxing ZhuFounder, Chairman & GM · born 1972
- Mr. Dongye ZhangAccounting Supervisor & CFO · born 1973
- Mr. Yingming WangDeputy GM & Director · born 1975
- Mr. Yujian ZhaoDeputy GM & Director · born 1972
- Mr. Duqiang WangDeputy GM, Secretary & Director · born 1985